Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Acquisition

2 Mar 2015 07:00

RNS Number : 1735G
Scapa Group PLC
02 March 2015
 



 

 

 

 

2 March 2015

 

Scapa Group plc

 

Acquisition of First Water Limited ("First Water" or "the Acquisition") and trading update

 

Scapa Group plc ("Scapa"), a global supplier of bonding materials and solutions, is pleased to announce that it has acquired 100% of the issued share capital of First Water Limited ("First Water") based in Ramsbury, UK. The purchase price is comprised of an initial cash consideration of £11.3m with a further cash consideration of up to £4m payable depending on performance in 2016, 2017 and 2018, for a total consideration of up to £15.3m.

 

As at 31 January 2015, unaudited gross assets acquired were £4.0m. Underlying EBITDA for the 12 months to 31 January 2015 was £0.9m on sales of £5.4m. The Acquisition is expected to be earnings enhancing in its first year.

 

First Water has built a reputation as one of the leading designer-manufacturers of advanced wound dressings and skin adhesives. Its patented adhesive polymers and dressing designs allow it to offer its OEM partners - typically multinational woundcare and consumer wellness companies - unique and compelling products for a wide range of clinical and commercial applications.

 

Background to the Acquisition

Scapa's strategy in healthcare is to become the outsourcing partner of choice to our global healthcare customers by offering turn-key solutions in our chosen market sectors of advanced woundcare, consumer wellness, medical devices and drug delivery. We believe we are well positioned to exploit the current trend in healthcare towards outsourcing while increasing our share of customers' total spend. The addition of First Water's strong patent portfolio and technological knowhow to Scapa's expertise in materials, coating and conversion capabilities significantly enhances the value proposition to our customers. First Water also brings a global customer base to which we can offer our full capabilities, leveraging our global footprint to accelerate First Water's growth.

 

First Water's highly experienced management team will remain within the enlarged Group and will strengthen Scapa's Healthcare management expertise and further facilitate the Group's growth in this sector.

 

Details of the Acquisition agreement

Scapa has acquired 100% of the issued share capital of First Water for an initial cash consideration of £11.3m (subject to adjustment following the production of a completion balance sheet to ensure normalised working capital). 

 

Three further cash payments of up to £4m in aggregate will be payable depending upon the achievement of operating profit targets over the following three financial years. The Acquisition will be funded from existing cash reserves and bank facilities.

 

Benefits of the Acquisition

The Directors believe that the Acquisition brings the following advantages to Scapa:

 

- a strengthened turn-key value proposition

- a broadened healthcare technology portfolio with proprietary and patented products

- enhanced innovation and development capabilities

- adds new global customers and potential markets

- the opportunity to leverage global sales channels providing significant cross-selling opportunities and product development potential

- improved global manufacturing infrastructure

- further acceleration of the growth of the Group's Healthcare business

- the Acquisition is expected to be earnings enhancing in the first full year of acquisition

 

Commenting on the Acquisition, Heejae Chae, Chief Executive of Scapa Group, said:

"The acquisition of First Water further enhances our strategy in healthcare to provide turn-key solutions as a strategic outsourcing partner to our global customers. First Water has a strong track record of delivering proven proprietary innovations and technologies which Scapa can now offer to our customers in consumer wellness and advanced woundcare markets in addition to expanding our offering in the medical device and drug delivery markets. Combining Scapa's strengths in material coating, converting and packaging with First Water's R&D and innovation capabilities will enable us to provide a unique one stop solution to our customers."

 

Commenting on the Acquisition, Justin Barnes and Phil Andrews, Co-owners and Directors of First Water, said:

"Becoming part of Scapa's rapidly growing global Healthcare business is a very exciting new chapter in First Water's development. From the outset, it was evident that there is great overlap and opportunity in terms of the enhanced global footprint and technology combinations that the expanded group can access. However, as important to the shareholders and employees of First Water, it was also clear that we share a common culture, a passion for what we do, and considerable care for putting our customers' priorities first. It will remain business as usual but with so much more horizon and opportunity."

 

Scapa Group current trading update

Whilst the year is not yet finished it is anticipated that the Group will have seen good growth over the same period last year, despite currency headwinds. It is anticipated that trading profits will be ahead of market expectations and we look forward to the forthcoming year with confidence. 

 

Scapa Group plc will issue a pre close update on the 9 April 2015.

 

 

 

 

Enquiries:

Scapa Group plc

Heejae Chae - Chief Executive

Paul Edwards - Finance Director

 

 

0161 301 7430

 

Numis Securities Limited

(Nominated Adviser and Joint Broker)

Mark Lander / Richard Thomas

 

 

 

020 7260 1000

 

N+1 Singer (Joint Broker)

Nick Owen

 

 

020 7496 3000

 

Weber Shandwick (Financial PR)

Nick Oborne

 

 

020 7067 0721

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQBCGDXGBGBGUB
Date   Source Headline
23rd Dec 20143:48 pmRNSHolding(s) in Company
10th Dec 20141:09 pmRNSHolding(s) in Company
2nd Dec 201410:00 amRNSDirectorate Change
1st Dec 201410:07 amRNSHolding(s) in Company
1st Dec 201410:03 amRNSHolding(s) in Company
26th Nov 20142:09 pmRNSAdditional Listing
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20149:08 amRNSHolding(s) in Company
18th Nov 20149:27 amRNSHolding(s) in Company
29th Oct 20143:33 pmRNSHolding(s) in Company
9th Oct 20147:00 amRNSTrading Statement
11th Aug 20147:00 amRNSDirector/PDMR Shareholding
7th Aug 20147:00 amRNSBlocklisting Interim Review
6th Aug 20149:03 amRNSDirector/PDMR Shareholding
23rd Jul 20147:00 amRNSDirector/PDMR Shareholding
22nd Jul 20145:04 pmRNSHolding(s) in Company
22nd Jul 20147:00 amRNSAGM Statement
11th Jun 20147:00 amRNSCompany Listing
9th Jun 20147:00 amRNSDirector/PDMR Shareholding
30th May 20143:44 pmRNSHolding(s) in Company
28th May 20147:00 amRNSFinal Results
16th May 20149:29 amRNSHolding(s) in Company
13th May 20143:08 pmRNSHolding(s) in Company
28th Apr 20144:20 pmRNSHolding(s) in Company-AMENDMENT
25th Apr 20142:58 pmRNSHolding(s) in Company
11th Apr 20149:45 amRNSHolding(s) in Company
10th Apr 20147:00 amRNSTrading Statement
3rd Apr 201410:24 amRNSAdditional Listing
13th Mar 20145:17 pmRNSHolding(s) in Company
12th Mar 20142:31 pmRNSAdditional Listing
6th Mar 20149:23 amRNSHolding(s) in Company
3rd Mar 20141:11 pmRNSHolding(s) in Company
18th Feb 20143:52 pmRNSHolding(s) in Company
7th Feb 20147:00 amRNSBlocklisting Interim Review
6th Feb 20147:00 amRNSMerger of UK Pension Schemes
29th Jan 20147:00 amRNSNew Finance Facility
9th Jan 20149:12 amRNSHolding(s) in Company
20th Dec 20138:42 amRNSHolding(s) in Company
11th Dec 20135:21 pmRNSHolding(s) in Company
11th Dec 20137:00 amRNSDirector/PDMR Shareholding
10th Dec 20137:00 amRNSDirector/PDMR Shareholding
26th Nov 20137:00 amRNSHalf Yearly Report
25th Nov 20134:09 pmRNSHolding(s) in Company
5th Nov 201312:11 pmRNSHolding(s) in Company
10th Oct 20137:00 amRNSTrading Statement
27th Sep 20137:00 amRNSHolding(s) in Company
7th Aug 20134:52 pmRNSHolding(s) in Company
7th Aug 20138:57 amRNSBlocklisting Interim Review
26th Jul 20138:47 amRNSHolding(s) in Company
26th Jul 20138:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.